4D Molecular (NASDAQ: FDMT) director gets 50,000 stock options grant

Rhea-AI Filing Summary

4D Molecular Therapeutics director Susannah Gray received a grant of stock options for 50,000 shares of common stock. The options have an exercise price of $9.42 per share and expire on June 16, 2036. One-third of the options vest on June 17, 2027, with the remainder vesting in equal monthly installments until fully vested on June 17, 2029, as long as she continues serving the company. The options were automatically granted under the non-employee director compensation program, and this grant brings her direct option holdings reported in this filing to 50,000 shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider GRAY SUSANNAH

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	50,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 50,000 shares (Direct, null)

Footnotes (1)

1. Automatically granted pursuant to the terms of the Company's non-employee director compensation program. The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).

Key Figures

Option grant size: 50,000 shares Exercise price: $9.42 per share Total options after grant: 50,000 shares +3 more

6 metrics

Option grant size 50,000 shares Stock Option (Right to Buy) granted to director

Exercise price $9.42 per share Exercise price of newly granted options

Total options after grant 50,000 shares Total derivative securities following transaction

Option expiration date June 16, 2036 Expiration of the stock option grant

Initial vesting date June 17, 2027 1/3 of options vest on this date

Final vesting date June 17, 2029 Options fully vested by this date

Key Terms

Stock Option (Right to Buy), non-employee director compensation program, Change in Control, 2020 Incentive Award Plan

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

non-employee director compensation program financial

"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."

Change in Control financial

"Additionally, the stock options will vest in full upon the consummation of a Change in Control"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

2020 Incentive Award Plan financial

"Change in Control (as defined in the 2020 Incentive Award Plan)."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GRAY SUSANNAH

(Last) (First) (Middle)

C/O 4D MOLECULAR THERAPEUTICS, INC.

5858 HORTON STREET #455

(Street)

EMERYVILLE CALIFORNIA 94608

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
4D Molecular Therapeutics, Inc. [ FDMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.42	06/17/2026		A(1)		50,000		(2)	06/16/2036	Common Stock	50,000	$0	50,000	D

Explanation of Responses:

1. Automatically granted pursuant to the terms of the Company's non-employee director compensation program.

2. The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).

	/s/ Scott Bizily as Attorney-in-Fact for Susannah Gray	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did FDMT director Susannah Gray report in this Form 4 filing?

FDMT director Susannah Gray reported receiving a grant of stock options for 50,000 shares of common stock. These options were automatically issued under the company’s non-employee director compensation program as part of her board service compensation package.

What is the exercise price of Susannah Gray’s new 4D Molecular FDMT stock options?

The newly granted FDMT stock options have an exercise price of $9.42 per share. This is the price per share Gray must pay to purchase common stock if and when she chooses to exercise the options in the future.

How do the 50,000 FDMT stock options granted to Susannah Gray vest over time?

One-third of Gray’s 50,000 FDMT stock options vest on June 17, 2027. The remaining options vest in equal monthly installments thereafter, fully vesting on June 17, 2029, contingent on her continued service to 4D Molecular Therapeutics.

When do Susannah Gray’s FDMT stock options expire if not exercised?

The options granted to Gray expire on June 16, 2036, if not exercised before that date. After expiration, she would no longer be able to purchase FDMT common stock under this particular stock option grant.

Under what program were the FDMT stock options granted to Susannah Gray?

The FDMT stock options were automatically granted under 4D Molecular Therapeutics’ non-employee director compensation program. The grant is made pursuant to the company’s 2020 Incentive Award Plan, which governs the terms and conditions of these equity awards.

Do Susannah Gray’s FDMT stock options have any special vesting provisions on a change in control?

Yes. The filing states that Gray’s FDMT stock options will vest in full upon the consummation of a Change in Control, as defined in the company’s 2020 Incentive Award Plan, regardless of the regular time-based vesting schedule.